ESTRO 2024 - Abstract Book

S260

Brachytherapy - Gynaecology

ESTRO 2024

Figure 1: 3D-printed custom applicator (left) and equivalent standard of care wax mould (right) designed for a clinical patient being treated for recurrent primary vaginal cancer.

Structure

DVH metric

Wax mould

3D-printed applicator

CTV

D90 (%)

100.8

100.1

CTV

D98 (%)

89.6

90.6

CTV

D0.1cc (%)

209.7

194.3

CTV

D2cc (%)

129.1

127.1

CTV

V150 (%)

22.8

20.3

CTV

V200 (%)

3.5

1.7

CTV

DHI

0.75

0.77

Bladder

D2cc (Gy)

0.67

0.58

Rectum

D2cc (Gy)

1.61

1.82

Table1: Plan dosimetry comparison for targets and OARs in the custom wax mould vs 3D-printed applicator plan geometries.

Conclusion:

The implementation of custom 3D-printed HDR-BT applicators for gynaecological cancers is clinically feasible. The Adaptiiv vendor-based software solution facilitates the efficient and accurate production of custom 3D-printed applicators, providing advantages over manual standard of care methods in terms of human resources, preparation time, accuracy of applicator positioning, replication of planned geometry and optimisation of plan dosimetry.

Keywords: 3D-printed applicators, clinical implementation

1953

Digital Poster

Dosimetric comparison between different applicators for high dose rate gynecologic brachytherapy

Andres Portocarrero-Bonifaz 1 , Salman Syed 2 , Maxwell Kassel 2 , Grant W McKenzie 2 , Vishwa M Shah 3 , Bryce Forry 2 , Adrianna H Masters 2 , Jeremy T Gaskins 4 , Keith T Sowards 2 , Scott R Silva 2 1 CARTI Cancer Center, Radiation Oncology, Little Rock, USA. 2 University of Louisville School of Medicine, Radiation Oncology, Louisville, USA. 3 University of Louisville School of Medicine, Gynecologic Oncology, Louisville, USA.